Literature DB >> 3740987

Severe dermatomyositis treated with cyclosporin A.

L Ejstrup.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3740987      PMCID： PMC1001948          DOI： 10.1136/ard.45.7.612-b

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  7 in total

1.  Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis.

Authors:  A Bohan; J B Peter; R L Bowman; C M Pearson
Journal:  Medicine (Baltimore)       Date:  1977-07       Impact factor: 1.889

2.  Cyclosporin for acute dermatomyositis.

Authors:  P Zabel; G Leimenstoll; W L Gross
Journal:  Lancet       Date:  1984-02-11       Impact factor: 79.321

3.  Cyclosporin blood levels do correlate with clinical complications.

Authors:  E Irschik; H Tilg; D Niederwieser; G Gastl; C Huber; R Margreiter
Journal:  Lancet       Date:  1984-09-22       Impact factor: 79.321

4.  Cyclosporin for polymyositis.

Authors:  K Bendtzen; N Tvede; V Andersen; G Bendixen
Journal:  Lancet       Date:  1984-04-07       Impact factor: 79.321

5.  Skin cancer in renal transplant patients treated with cyclosporin.

Authors:  J F Thompson; R Allen; P J Morris; R Wood
Journal:  Lancet       Date:  1985-01-19       Impact factor: 79.321

6.  Cyclosporin-associated fatal convulsions.

Authors:  T Velu; L Debusscher; P A Stryckmans
Journal:  Lancet       Date:  1985-01-26       Impact factor: 79.321

7.  [Cyclosporin A. A different immunosuppressive agent].

Authors:  K Bendtzen
Journal:  Ugeskr Laeger       Date:  1983-09-05
  7 in total
  8 in total

Review 1.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

2.  Cyclosporin for dermatomyositis.

Authors:  S Levi; H J Hodgson
Journal:  Ann Rheum Dis       Date:  1989-01       Impact factor: 19.103

Review 3.  Recognition and management of myositis.

Authors:  P Cherin
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 4.  Immunosuppressive drugs and corticosteroids in the treatment of rheumatoid arthritis.

Authors:  M Arnold; L Schrieber; P Brooks
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

5.  Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis.

Authors:  M G Danieli; G Malcangi; C Palmieri; F Logullo; A Salvi; M Piani; G Danieli
Journal:  Ann Rheum Dis       Date:  2002-01       Impact factor: 19.103

Review 6.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

7.  Cyclosporin in the management of polymyositis and dermatomyositis.

Authors:  C J Lueck; P Trend; M Swash
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-11       Impact factor: 10.154

Review 8.  Protein-losing Gastroenteropathy Related to Mixed Connective Tissue Disease: A Case Report of a Successful Outcome and Literature Review.

Authors:  Yuya Kobayashi; Yasuhiro Shimojima; Yasufumi Kondo; Ryota Takamatsu; Daigo Miyazaki; Dai Kishida; Yoshiki Sekijima; Shu-Ichi Ikeda
Journal:  Intern Med       Date:  2017-08-01       Impact factor: 1.271
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.